Dr. Reddy's Laboratories Ltd. Regulatory Clarification
Summary of Company's Response
Dr. Reddy's Laboratories Limited has responded to a clarification query from the National Stock Exchange of India (NSE) regarding a news article. The company confirmed the accuracy of the news about its antibiotic drug approval in Thailand and stated it had no material impact. The company affirmed its compliance with SEBI disclosure regulations.
Date and Nature of Exchange Query
- Date of Exchange Query: July 28, 2026 (received via email).
- NSE Reference Number: NSE/CM/Surveillance/17309.
- Nature of Query: The NSE sought clarification from the company regarding a news article published in Business Standard on July 28, 2026, with the headline "Dr Reddys antibiotic gets Thailand approval six months after US nod". The query was made under SEBI Listing Obligations and Disclosure Requirements.
Company's Clarification on News and Trading
- The company confirmed that the headline of the news article is correct.
- The news pertained to a joint press release issued by the company and the Global Antibiotic Research & Development Partnership Foundation (GARDP) on July 27, 2026.
- The press release was titled "Thai FDA approves NUZOLVENCE® (zoliflodacin) just six months after US authorization."
- The company stated that there were no ongoing negotiations related to this event, rendering that part of the query not applicable.
- The company confirmed it was not aware of any undisclosed information that could explain trading activity, stating that at this stage, there is no material event or information requiring disclosure.
Details of Financial Impact
- The company explicitly stated: "We believe there is no material impact of the above referred news article on the Company".